Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
Behavioural Treatment of Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2011-09-19
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 150
- Registration Number
- NCT00247910
- Locations
- 🇨🇦
UBC Hospital, Vancouver, British Columbia, Canada
Pharmacogenomic Evaluation of Antihypertensive Responses
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 1701
- Registration Number
- NCT00246519
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Florida Department of Community Health and Family Medicine, Gainesville, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
PHARES Study: Management of Resistant Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2011-02-28
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 180
- Registration Number
- NCT00224549
- Locations
- 🇫🇷
Investigation Clinical Center European Georges Pompidou Hospital, Paris, Ile de France, France
Treatment of Supine Hypertension in Autonomic Failure
- Conditions
- Hypertension
- Interventions
- Drug: PlaceboDrug: ClonidineDrug: Nitroglycerin transdermalDrug: Dipyridamole/ Aspirin (Aggrenox)Drug: Desmopressin (DDAVP)Drug: SildenafilDrug: NifedipineDrug: HydralazineDrug: HydrochlorothiazideDrug: BosentanDrug: DiltiazemDrug: EplerenoneDrug: guanfacineDietary Supplement: L-arginineDrug: captoprilDrug: carbidopaDrug: losartanDrug: metoprolol tartrateDrug: nebivolol hydrochlorideDrug: prazosin hydrochlorideDrug: tamsulosin hydrochlorideOther: Head-up tilt.Drug: aliskirenOther: Local heat stress
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 152
- Registration Number
- NCT00223717
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Olmesartan as an add-on to Amlodipine in Hypertension
- Conditions
- Essential Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 632
- Registration Number
- NCT00220233
Aldosterone and Vascular Disease in Diabetes Mellitus
- Conditions
- Diabetes MellitusEndothelial DysfunctionAlbuminuria
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-01-03
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00214825
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 110
- Registration Number
- NCT00185068
Olmesartan Medoxomil in Atherosclerosis
- Conditions
- Essential HypertensionAtherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-12-14
- Lead Sponsor
- Sankyo Pharma Gmbh
- Target Recruit Count
- 165
- Registration Number
- NCT00185185
Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-06-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 125
- Registration Number
- NCT00171054
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT00171132
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.